In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on GW Pharma (GWPH – Research Report), with a price target of $200. The company’s shares closed yesterday at $152.42.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 2.9% and a 45.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GW Pharma with a $218.38 average price target, a 43.3% upside from current levels. In a report issued on July 30, Piper Jaffray also maintained a Buy rating on the stock with a $210 price target.
Based on GW Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $50.6 million. In comparison, last year the company had a GAAP net loss of $35.27 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.